Quantcast
Last updated on April 19, 2014 at 7:10 EDT

Latest B-cell chronic lymphocytic leukemia Stories

2013-04-11 08:28:19

SUNNYVALE, Calif., April 11, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the Phase III clinical trial (RESONATE(TM)-2), a monotherapy trial using ibrutinib versus chlorambucil in elderly patients with newly diagnosed chronic lymphocytic leukemia / small lymphocyctic lymphoma (CLL/SLL) has enrolled its fifth patient. The enrollment of the fifth patient has subsequently triggered a fourth $50 million milestone payment obligation from Janssen Biotech, Inc., one...

2013-04-08 12:28:38

-Nine Ibrutinib Presentations at the American Association of Cancer Research - SUNNYVALE, Calif., April 8, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to...

2013-04-08 08:29:37

SUNNYVALE, Calif., April 8, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the U.S. Food and Drug Administration (FDA) has granted an additional Breakthrough Therapy Designation for the investigational oral agent ibrutinib as monotherapy for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients with deletion of the short arm of chromosome 17 (deletion 17p). Patients harboring a deletion within chromosome 17 generally...

2013-04-08 08:29:34

Designation granted in the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma with a genetic mutation, del17p RARITAN, N.J., April 8, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted a third Breakthrough Therapy Designation for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib. Ibrutinib has been granted Breakthrough...

2013-04-04 16:23:50

WHITE PLAINS, N.Y., April 4, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health agency funding many of today's breakthroughs in blood cancer treatments, including advances in targeted therapies, immunotherapies and epigenetics. Many LLS-funded researchers will be presenting results of some of their latest work at the 104(th) AACR Annual Meeting 2013, taking place at the Walter E. Washington Convention Center in Washington. D.C., April...

2013-03-26 11:03:41

Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells. The findings, published in the online Early Edition of the Proceedings of the National Academy of Sciences on March 25, 2013 represent a potential new therapy for treating at least some patients with CLL, the most common type of blood cancer in the United States. CLL cells express high levels...

Using T Cells To Fight Childhood Leukemia
2013-03-26 05:43:28

redOrbit Staff & Wire Reports - Your Universe Online A research team from The Children's Hospital of Philadelphia and the University of Pennsylvania used a novel cell therapy to reprogram the immune cells of two leukemia patients, resulting in a complete remission of the disease and a total lack of evidence of cancer cells in their bodies. The treatment, which is described in a study that is currently available online and will appear in the April 18 print edition of the New England...

2013-03-25 12:27:13

-- CHOP/Penn Medicine Oncology Team Reports Complete Remission in Pediatric ALL Patients PHILADELPHIA, March 25, 2013 /PRNewswire-USNewswire/ -- Two children with an aggressive form of childhood leukemia had a complete remission of their disease--showing no evidence of cancer cells in their bodies--after treatment with a novel cell therapy that reprogrammed their immune cells to rapidly multiply and destroy leukemia cells. A research team from The Children's Hospital of...

2013-03-22 08:25:02

LONDON, March 22, 2013 /PRNewswire/ -- Baxter International Inc. (NYSE: BAX) and Halozyme Therapeutics, Inc., (NASDAQ: HALO) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (EMA CHMP) has granted a Positive Opinion to Baxter for the use of HyQvia (solution for subcutaneous use) as replacement therapy for adult patients with primary and secondary immunodeficiencies. The product is a combination of human normal immunoglobulin (IGSC,...

2013-03-19 12:28:01

MEMPHIS, Tenn., March 19, 2013 /PRNewswire-USNewswire/ -- The United States Patent and Trademark Office today awarded St. Jude Children's Research Hospital U.S. patent number 8,399,645 for St. Jude's invention of compositions for genetically modifying human immune cells so they can destroy some of the most common forms of cancer in children and adults. "This groundbreaking invention enables human immune cells to recognize and attack certain cells that cause leukemia and lymphoma, cancers...